Hear from the Experts in HR+/HER2- Breast Cancer Treatment at Our Upcoming Webinar
Join us for an enlightening webinar on the latest expert insights for hormone receptor-positive and HER2-negative breast cancer. This subtype, which is characterized by the presence of hormone receptors but lacks HER2 protein overexpression, represents a significant portion of breast cancer cases and generally has a favorable prognosis with a range of effective treatment options available.
Our expert panelists include Dr. Joyce O’Shaughnessy, a renowned medical oncologist and leading voice in breast cancer. She will bring her vast experience and insight to the panel. As the Director of Breast Cancer Research at Baylor Charles A. Sammons Cancer Center and Chair of the Breast Disease Committee at the Sarah Cannon Research Institute, Dr. O’Shaughnessy’s contributions to the field have helped to shape current breast cancer therapies. In addition, Dr. Adrienne Waks of the Dana-Farber Cancer Institute will also join us, sharing her expertise in breast oncology and novel treatment strategies. As an Assistant Professor of Medicine at Harvard Medical School and the Associate Director of Breast Oncology Clinical Research, Dr. Waks brings a fresh perspective on integrating innovative therapies into clinical practice.
During the discussion, our distinguished panelists will cover a range of compelling topics, aiming to deepen understanding and update attendees on the latest developments in HR+/HER2- breast cancer management:
- Personalized Treatment Strategies: Recent advancements in genomic profiling and biomarker research are tailoring treatments to individual patient profiles, enhancing efficacy while potentially reducing side effects.
- Integrating Immunotherapy: Combining traditional therapies with immunotherapy represents a frontier in cancer treatment. Our experts will discuss the benefits and challenges of these combinations, providing insights into how they are changing the treatment landscape.
- Advancements in CDK4/6 Inhibitors: A focus will be given to the role of CDK4/6 inhibitors in managing advanced HR+/HER2- breast cancer. The discussion will include current impacts and future developments that are expected in this area.
- Improving Patient Selection for Novel Therapies: The effectiveness of new treatments can often depend on selecting suitable patients. Our experts will cover how patient selection processes are evolving and what steps are being taken to improve these methods.
- Emerging Treatments for Overcoming Endocrine Resistance: Discover the latest treatment modalities that show promise in overcoming resistance to endocrine therapy, a common challenge in managing HR+/HER2- breast cancer.
- Future Directions in Research and Treatment: The webinar will glimpse the most promising areas of breast cancer research and the potential upcoming breakthroughs that could significantly affect patient outcomes.
- Balancing Treatment Efficacy with Quality of Life: Finally, the discussion will address how clinicians can balance aggressive treatment strategies with maintaining quality of life for breast cancer patients.
We have designed this to be of interest to anyone dedicated to advancing their knowledge and expertise in breast cancer care, including clinicians, researchers, patients, caregivers, and pharmaceutical industry personnel. Whether you are directly involved in patient care or the broader scope of cancer research and treatment development, this webinar will provide valuable insights that could impact your work and patient outcomes. Join us to engage with leading experts and stay at the forefront of breast cancer treatment innovation.
About Cadence
Founded in 2008, Cadence Communications & Research is a woman-owned professional services firm focused on the healthcare sector. Cadence supports its clients through market research, meeting planning, logistics support, content development, and industry-leading system for managing relationships with opinion leading physicians.
Contact Emily Anderson at eanderson@cadenceresearch.com.
